Vertex Pharmaceuticals Incorporated $VRTX Holdings Raised by Somerville Kurt F

Somerville Kurt F increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.4% in the 2nd quarter, Holdings Channel.com reports. The fund owned 23,186 shares of the pharmaceutical company’s stock after buying an additional 310 shares during the quarter. Vertex Pharmaceuticals comprises about 1.7% of Somerville Kurt F’s holdings, making the stock its 24th biggest position. Somerville Kurt F’s holdings in Vertex Pharmaceuticals were worth $10,322,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Vertex Pharmaceuticals by 1.0% during the first quarter. Vanguard Group Inc. now owns 23,491,161 shares of the pharmaceutical company’s stock valued at $11,388,985,000 after buying an additional 232,873 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of Vertex Pharmaceuticals by 17.2% during the 1st quarter. Jennison Associates LLC now owns 5,062,442 shares of the pharmaceutical company’s stock valued at $2,454,373,000 after acquiring an additional 744,680 shares during the last quarter. Alliancebernstein L.P. raised its stake in shares of Vertex Pharmaceuticals by 0.9% in the 1st quarter. Alliancebernstein L.P. now owns 3,953,512 shares of the pharmaceutical company’s stock valued at $1,916,742,000 after acquiring an additional 33,492 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Vertex Pharmaceuticals by 72.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,917,227 shares of the pharmaceutical company’s stock valued at $1,414,331,000 after acquiring an additional 1,226,527 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Vertex Pharmaceuticals by 9.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,559,476 shares of the pharmaceutical company’s stock worth $1,240,885,000 after purchasing an additional 230,257 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of VRTX stock opened at $410.28 on Wednesday. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $519.88. The stock has a fifty day moving average price of $396.79 and a 200 day moving average price of $441.11. The stock has a market cap of $105.19 billion, a P/E ratio of 29.33 and a beta of 0.43.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. The company had revenue of $2.94 billion during the quarter, compared to analysts’ expectations of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business’s revenue was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Analyst Ratings Changes

VRTX has been the subject of several recent analyst reports. Citigroup upped their price objective on shares of Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a “buy” rating in a report on Thursday, October 2nd. BMO Capital Markets set a $530.00 target price on shares of Vertex Pharmaceuticals and gave the stock an “outperform” rating in a research report on Tuesday, August 5th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a research report on Saturday, September 27th. Leerink Partnrs upgraded Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 25th. Finally, Evercore ISI decreased their target price on Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating for the company in a research note on Thursday, September 11th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $493.81.

Insider Buying and Selling

In related news, Director Bruce I. Sachs acquired 5,000 shares of the firm’s stock in a transaction on Wednesday, August 6th. The shares were bought at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the acquisition, the director owned 45,000 shares of the company’s stock, valued at $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.